These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 38488426

  • 1. Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysis.
    Deng JH, Lai PH, Xie LS, Qiu SS, Qiu DS, Zhang JX.
    Clin Transl Sci; 2024 Mar; 17(3):e13757. PubMed ID: 38488426
    [Abstract] [Full Text] [Related]

  • 2. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
    Liu CW, Chang WC, Lee CC, Shau WY, Hsu FS, Wang ML, Chen TC, Lo C, Hwang JJ.
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
    [Abstract] [Full Text] [Related]

  • 3. Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study.
    Su CY, Shen LJ, Hsieh SC, Lin LY, Lin FJ.
    Mayo Clin Proc; 2019 Jul; 94(7):1147-1157. PubMed ID: 31272565
    [Abstract] [Full Text] [Related]

  • 4. The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.
    Wang M, Zhang Y, Zhang M, Li H, Wen C, Zhao T, Xie Z, Sun J.
    Ann Palliat Med; 2021 Oct; 10(10):10327-10337. PubMed ID: 34498481
    [Abstract] [Full Text] [Related]

  • 5. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
    Zhang M, Solomon DH, Desai RJ, Kang EH, Liu J, Neogi T, Kim SC.
    Circulation; 2018 Sep 11; 138(11):1116-1126. PubMed ID: 29899013
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis.
    Gao L, Wang B, Pan Y, Lu Y, Cheng R.
    Clin Cardiol; 2021 Jul 11; 44(7):907-916. PubMed ID: 34013998
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat.
    Shin A, Choi SR, Han M, Ha YJ, Lee YJ, Lee EB, Kang EH.
    Semin Arthritis Rheum; 2022 Oct 11; 56():152080. PubMed ID: 35973263
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.
    MacDonald TM, Ford I, Nuki G, Mackenzie IS, De Caterina R, Findlay E, Hallas J, Hawkey CJ, Ralston S, Walters M, Webster J, McMurray J, Perez Ruiz F, Jennings CG, Members of the FAST Study Group.
    BMJ Open; 2014 Jul 10; 4(7):e005354. PubMed ID: 25011991
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials.
    Xie H, Hu N, Pan T, Wu JC, Yu M, Wang DC.
    BMC Pharmacol Toxicol; 2023 Dec 14; 24(1):79. PubMed ID: 38098046
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
    Barrientos-Regala M, Macabeo RA, Ramirez-Ragasa R, Pestaño NS, Punzalan FER, Tumanan-Mendoza B, Castillo RR.
    J Cardiovasc Pharmacol; 2020 Oct 14; 76(4):461-471. PubMed ID: 32675751
    [Abstract] [Full Text] [Related]

  • 14. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.
    White WB, Chohan S, Dabholkar A, Hunt B, Jackson R.
    Am Heart J; 2012 Jul 14; 164(1):14-20. PubMed ID: 22795277
    [Abstract] [Full Text] [Related]

  • 15. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
    Choi H, Neogi T, Stamp L, Dalbeth N, Terkeltaub R.
    Arthritis Rheumatol; 2018 Nov 14; 70(11):1702-1709. PubMed ID: 29869840
    [Abstract] [Full Text] [Related]

  • 16. Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.
    Ju C, Lai RWC, Li KHC, Hung JKF, Lai JCL, Ho J, Liu Y, Tsoi MF, Liu T, Cheung BMY, Wong ICK, Tam LS, Tse G.
    Rheumatology (Oxford); 2020 Sep 01; 59(9):2340-2349. PubMed ID: 31873735
    [Abstract] [Full Text] [Related]

  • 17. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.
    Faruque LI, Ehteshami-Afshar A, Wiebe N, Tjosvold L, Homik J, Tonelli M.
    Semin Arthritis Rheum; 2013 Dec 01; 43(3):367-75. PubMed ID: 24326033
    [Abstract] [Full Text] [Related]

  • 18. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study.
    Kang EH, Choi HK, Shin A, Lee YJ, Lee EB, Song YW, Kim SC.
    Rheumatology (Oxford); 2019 Dec 01; 58(12):2122-2129. PubMed ID: 31098635
    [Abstract] [Full Text] [Related]

  • 19. [Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)].
    Alten R, Mischkewitz M, Nitschmann S.
    Internist (Berl); 2020 May 01; 61(5):530-532. PubMed ID: 32130437
    [No Abstract] [Full Text] [Related]

  • 20. The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
    Wang S.
    Pak J Pharm Sci; 2018 Jul 01; 31(4(Special)):1623-1627. PubMed ID: 30203749
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.